Patent application number | Description | Published |
20090105310 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds and Methods of Use - Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included. | 04-23-2009 |
20090209556 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS - A compound having the structure | 08-20-2009 |
20090209564 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use - Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included. | 08-20-2009 |
20100004158 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE - Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included. (I) | 01-07-2010 |
20100144824 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE - Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included. | 06-10-2010 |
20100216764 | Soluble Guanylate Cyclase Activators - This inventions relates to compounds having the structure Formula I | 08-26-2010 |
20110118282 | Soluble Guanylate Cyclase Activators - A compound having the structure | 05-19-2011 |
20130210798 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS - This inventions relates to compounds having the structure Formula I and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver. | 08-15-2013 |
20140206681 | BTK INHIBITORS - The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I | 07-24-2014 |
20140221333 | BTK INHIBITORS - Provided are 6-5 membered fused pyridine ring compounds according to Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders. | 08-07-2014 |